Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

This study is testing whether a drug called mitoxantrone can overcome resistance to venetoclax — a targeted cancer therapy — in people with acute myeloid leukemia (AML) whose cancer has stopped responding to venetoclax-based first-line treatment. It is examining both patients with early signs of remaining cancer and those with frank relapse. **You may be eligible if...** - You have been diagnosed with AML (excluding a specific subtype called APL) - You were previously treated with venetoclax combined with a hypomethylating agent (azacitidine or decitabine) as your first treatment - Your cancer has relapsed or did not respond adequately to that treatment - You are in generally good health and able to care for yourself (ECOG 0–2) - Your kidney, liver, and heart function are within acceptable ranges - Your heart pumps at more than 50% of normal capacity (LVEF above 50%) **You may NOT be eligible if...** - Your AML has spread to the brain or spinal fluid - You have significant active heart disease, including recent heart attack or severe heart failure - You have serious kidney, liver, neurological, psychiatric, or metabolic conditions unrelated to your leukemia - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.